E-viri
Recenzirano
-
Martinez, Jeremy; Manjaly, Cyriac; Manjaly, Priya; Ly, Sophia; Zhou, Guohai; Barbieri, John; Mostaghimi, Arash
JAMA dermatology (Chicago, Ill.), 12/2023, Letnik: 159, Številka: 12Journal Article
Janus kinase (JAK) inhibitors are increasingly used across a range of dermatologic conditions. Adverse events of acne have been noted in some studies in clinical practice, but the scope of this outcome across JAK inhibitors has not been established. To systematically analyze all published phase 2 and 3 placebo-controlled randomized clinical trials (RCTs) of JAK inhibitors for the risk of acne as an adverse effect of these medications. Comprehensive search of Ovid MEDLINE and PubMed databases through January 31, 2023. Inclusion criteria were phase 2 and 3 placebo-controlled RCTs of JAK inhibitors published in English with reported adverse events of acne. Two reviewers independently reviewed and extracted information from all included studies. The primary outcome of interest was the incidence of acne following JAK inhibitor use. A meta-analysis was conducted using random-effects models. A total of 25 unique studies (10 839 unique participants; 54% male and 46% female) were included in the final analysis. The pooled odds ratio (OR) was calculated to be 3.83 (95% CI, 2.76-5.32) with increased ORs for abrocitinib (13.47 95% CI, 3.25-55.91), baricitinib (4.96 95% CI, 2.52-9.78), upadacitinib (4.79 95% CI, 3.61-6.37), deucravacitinib (2.64 95% CI, 1.44-4.86), and deuruxolitinib (3.30 95% CI, 1.22-8.93). Estimated ORs were higher across studies investigating the use of JAK inhibitors for the management of dermatologic compared with nondermatologic conditions (4.67 95% CI, 3.10-7.05) as well as for JAK1-specific inhibitors (4.69 95% CI, 3.56-6.18), combined JAK1 and JAK2 inhibitors (3.43 95% CI, 2.14-5.49), and tyrosine kinase 2 inhibitors (2.64 95% CI, 1.44-4.86). In this systematic review and meta-analysis, JAK inhibitor use was associated with an elevated odds of acne. Patients should be properly counseled on this potential adverse effect of these medications before treatment initiation. Future studies are needed to further elucidate the pathophysiology of this association.
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.